Management of Pharmaceutical Resources for the Primary Prevention of Coronary Heart Disease in Catalonia (Spain) Based on Efficiency and Equity
Tóm tắt
The objective of the study was to develop a procedure to distribute health resources among treatments for the primary prevention of coronary heart disease based on efficiency and equity. Two procedures to manage pharmaceutical resources for the primary prevention of coronary heart disease in Catalonia, Spain, were developed in this study. The following treatments were considered in these procedures: medical advice and nicotine substitution therapies for smoking cessation; hydrochlorothiazide (diuretic) and propranolol (β-adrenergic antagonist) for moderate/severe hypertension; hydrochlorothiazide and nifedipine (calcium antagonist) for mild hypertension; and lovastatin (HMG-CoA reductase inhibitor) for hypercholesterolemia higher than 7.23 mmol/L or 2.7 g/L. The first procedure was developed based on decision rules of cost-effectiveness analysis, giving a higher priority to treatments with a higher cost effectiveness. The second procedure was developed based on efficiency and equity, deciding allocation of resources based on cost-effectiveness and social preferences. Annual cost of treatments ranged from $US147.30 per individual for smoking cessation to $US2555.20 per individual for treatment with lovastatin 80 mg/day (1998 values). Resources should be allocated in the following order, according to the procedure based on decision rules of cost-effectiveness analysis, to smoking cessation therapies, hypertension treatments and hypercholesterolemia treatments. This is in contrast to the procedure based on efficiency and equity, where a higher priority should be given to the most cost-effective treatment for hypertension, hypercholesterolemia and smoking. The efficiency and equity strategy could reduce the amount of resources necessary to treat all individuals at risk by 26 to 47%, according to age and gender. The procedure based on efficiency alone should be used when the objective is to maximize health gains from available resources. The procedure based on both efficiency and equity should be used when society has an aversion to inequality in the distribution of health gains, treating all individuals with coronary heart disease risk factors at the lowest cost.
Tài liệu tham khảo
Hepler CD, Wertheimer AI, Navarro RP, editors. Management of drug therapy in health programs. New York: Pharmaceutical Products Press, 1999: 165–76
Epstein RS, McGlynn MG. Disease management: what is it? Dis Manage Health Outcomes 1997; 1: 3–10
Plans-Rubió P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease. Pharmacoeconomics 1998; 13: 623–43
Plans-Rubió P. Cost-effectiveness of cardiovascular prevention programs in Spain. Int J Technol Assess Health Care 1998; 14: 320–30
Weinstein MC, Stasson WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296:716–21
Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
Wagstaff A. QALY and the equity-efficiency trade-off. J Health Econ 1991; 10: 21–41
Birch S, Gafni A. Cost-effectiveness/utility analysis. Do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279–96
Ubel PA, de Kay ML, Baron J, et al. Cost-effectiveness analysis in a setting of budget constraints. Is it equitable? N Engl J Med 1996; 334: 1174–7
The Expert Panel. Second Report of the National Cholesterol Education Program on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994; 89: 1333–445
Task Force Report. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Join Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434–503
Joint Committee on Detection, Evaluation and Treatment of High Blood Pressure. Report of the Joint Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154–83
Catálogo de Especialidades Farmacéuticas. Madrid: Publicaciones del Consejo General de Colegios Oficiales de Farmacéuticos, 1992
National Institute of Health. Economic report on health institutionsonómico-funcional de las Instituciones Sanitarias, 1987–110. Madrid: Ministerio de Sanidad y Consumo, 1992
Gold MR, Siegel JE, Russell LB, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
Abbott RD, McGee D. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. In: Kannel WB, Wolf PA, Garrisson RJ, editors. Bethesda (MD): US Department of Health, Education and Welfare, 1987
Glick H, Hayse JF, Thomson RS, et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Pennsylvania: Leonard Davis Institute of Health Economics, University of Pennsylvania, 1990
Weinstein MC, Stasson WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716–21
Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993; 12: 459–67
Drummond MF, Os’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997
Weinstein MC. Principles of cost-effectiveness resource allocation in health care organizations. Int J Technol Assess Health Care 1990; 6: 93–103
Plans P, Pardell H, Salleras L. Epidemiology of cardiovascular disease risk factors in Catalonia (Spain). Eur J Epidemiol 1993; 9: 381–9
Grabowski H, Mullins D. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 1997; 45: 535–44
Granata AV, Hillman AL. Competing practice guidelines: using cost-effectiveness analysis to make optimal decisions. Ann Intern Med 1998; 128: 56–63
Dolan P. The measurement of individual utility and social welfare. J Health Econ 1998; 17: 39–52
Lyles A, Palumbo FB. The effect of managed care on prescription drug costs and benefits. Pharmacoeconomics 1999; 15: 129–40
Smith DG. The effects of co-payments and generic substitution on the use and costs of prescription drugs. Inquiry 1993; 30: 189–98
Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and costs of Pharmaceuticals in a health maintenance organization. Med Care 1990; 28: 907–17
Stergachis A, Sullivan SD, Penna PM, et al., editors. The application of pharmacoeconomics in managed health care settings. Principles of pharmacoeconomics. Cincinnati (OH): Witney Co., 1996